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Background: Patients with diabetes mellitus (DM) undergoing percutaneous cardiovascular intervention (PCI) represent a challenging population 
at higher risk for adverse events including late mortality following drug-eluting stent treatment. Long-term outcomes in patients with DM following 
PCI with the R-ZES have not been described.
Methods: The RESOLUTE Clinical Trial Program consists of includes 5 studies: the randomized RESOLUTE All Comers (R-AC, N=1140), plus 
RESOLUTE First-in-Man (N = 139), RESOLUTE US (N = 1402), RESOLUTE International (N = 2349), and RESOLUTE Japan (N = 100). Pooled data from 
1535 DM patients and 3595 non-DM patients were analyzed and compared. These data were also compared with outcomes from patients with and 
without DM receiving the everolimus-eluting stent (EES) on the R-AC trial (N=1152). Propensity scores were used to adjust for differences in patient 
and lesion characteristics.
Results: The diabetic population (29.6% insulin-dependent [IDDM]) was older with more females and more likely to have hypertension, 
hyperlipidemia, or prior PCI than non-DM patients. At 1 year there was no difference in rates of clinical-driven target lesion revascularization (TLR), 
cardiac death or myocardial infarction (CD/MI), or ARC definite/probable stent thrombosis (ST) between the non-IDDM patients and the non-DM 
patients but rates of TLR, CD/MI and ST were significantly greater for IDDM patients compared with non-DM patients (TLR; 6.3% vs 2.9%, p<0.001; 
CD/MI; 6.6% vs 3.6% p=0.003; ST; 1.5% vs 0.7%, p=0.02). Cumulative incidence of target lesion failure (TLF; cardiac death, target vessel MI and 
TLR) was similar for DM patients receiving the R-ZES (7.8%) and the EES (9.0%) at 1 year (p=0.96); there was a trend to lower TLF in the non-DM 
patients (R-ZES, 6.1%; EES, 8.3%, p=0.09). One year outcomes for R-ZES and EES DM patients were also similar for rates of TLR, CD/MI and ST.
Conclusions: Despite the higher risk nature of DM patients, the event rates in non-IDDM were similar to the non-DM population. At 1 year 
outcomes among DM patients receiving the EES or the R-ZES were not different. Patients with IDDM continue to be a challenging population. Further 
follow-up to 2 years will be reported.
